尼妥珠单抗联合放化疗治疗中晚期宫颈癌的疗效分析

Clinical study of nimotuzumab combined with chemoradiotherapy on middle-advanced stage of uterine cervical cancer

目的探讨靶向药物尼妥珠单抗联合同步放化疗治疗中晚期宫颈癌的疗效。方法 2008年6月至2010年6月在该科接受治疗的中晚期宫颈癌患者共62例,分为观察组30例,对照组32例。观察组采用尼妥珠单抗联合顺铂同步放化疗,对照组行单纯顺铂同步放化疗。比较两组的近期、远期疗效和不良反应。结果观察组及对照组的近期有效率分别为93.3%和90.6%,差异无统计学意义(P>0.05)。观察组的3年生存率83.3%、局部复发率7.1%与对照组的59.3%、31.3%相比,差异有统计学意义(P<0.05);两组的远处转移率分别为13.3%和18.8%,差异无统计学意义(P>0.05)。两组的近期及远期不良反应比较差异无统计学意义(P>0.05)。结论尼妥珠单抗联合同步放化疗可明显提高中晚期宫颈癌患者的3年生存率及局部控制率,且不良反应可以耐受。

Objective To investigate clinical efficacy of nimotuzumab Combined with chemoradiotherapy on middle-advanced stage of uterine cervical cancer. Methods Sixty-two patients with middle-advanced stage of uterine cervical cancer in our depart- ment from June 2008 to June 2010 were collected,and they were divided into two groups,30 cases in treatment group and 32 in con- trol group. In the treatment group, patients received therapy of nimotuzumab combined with chemoradiotherapy, and the patients in control group treated by cisplatin with chemoradiotherapy. The short-term, long-term efficacy and adverse reactions of the two groups were observed and followed up. Results The short-term efficiency of the treatment group and the control group were 93.3% and 90.6%,and the difference was not statistically significant （P〉0.05）. The three-year survival rate （83.3%） and local recurrence rate （7.1%） of the treatment group had difference with control group （59.3%, 31.3%）, and the difference was statisti- cally significant （P〈0. 05）, while the distant metastasis rates of the two groups were 13.3% and 18. 8%, the difference was not statistically significant （P〉0.05）. In the adverse reactions of the two group, the short-term toxicity and long-term toxicity were not significant difference （P〉0.05）. Conclusion Nimotuzumab combined with ：hemoradiotherapy could significantly improve 3-year survival and the local control rate for the patient with middle-advanced stage of uterine cervical cancer, and the adverse reactions can be tolerated.